Hyperbaric intra-thecal ropivacaine - a comparison with hyperbaric bupivacaine with respect to extent and duration of motor block

Submission date	Recruitment status	Prospectively registered
29/09/2006	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
29/09/2006	Completed	Results
Last Edited	Condition category	[] Individual participant data
23/04/2015	Surgery	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr John Duggan

Contact details

Wansbeck General Hospital Woodhorn Lane Ashington United Kingdom NE63 9JJ

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0504163841

Study information

Scientific Title

Hyperbaric intra-thecal ropivacaine - a comparison with hyperbaric bupivacaine with respect to extent and duration of motor block

Study objectives

- 1. Does intra-thecal hyperbaric ropivacaine result in motor block of shorter duration when compared with an equal dose of bupivacaine (of equal baricity and concentration)?
- 2. Furthermore, does intra-thecal hyperbaric ropivacaine produce a sensory block of similar extent and duration to an equal dose of intra-thecal bupivacaine of equal baricity and concentration?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Surgery: Anaesthesia

Interventions

40 patients undergoing spinal anaethesia would be recruited to our study and randomised to receive equal hyperbaric doses of either 0.5% bupivacaine in 8% glucose solution or 0.5% ropivacaine in 8% glucose solution. The solutions would be of similar anaesthesia under standardised conditions, we would measure a number of parameters of particular interest. After surgery, we would study the recovery profile of all recruited subjects for the duration of time taken to achieve complete neurological recovery. We would record strength of dorsi-flexion in 15 minute intervals and time to regression of sensory block.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Ropivacaine, bupivacaine

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/05/2005

Completion date

01/05/2006

Eligibility

Key inclusion criteria

- 1. Elective surgery
- 2. Patient and surgery appropriate for spinal anaesthesia
- 3. ASA grade <3
- 4. Age >18 years
- 5. Non-pregnant
- 6. No known sensitivities to amide class of local anaesthetics
- 7. Not currently or recently (<3 months) recruited to other clinical trials

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

40

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/05/2005

Date of final enrolment

01/05/2006

Locations

Countries of recruitment

England

United Kingdom

Study participating centre Wansbeck General Hospital

Ashington United Kingdom NE63 9JJ

Sponsor information

Organisation

Record Provided by the NHSTCT Register - 2006 Update - Department of Health

Sponsor details

The Department of Health Richmond House 79 Whitehall London United Kingdom SW1A 2NL +44 (0)20 7307 2622 dhmail@doh.gsi.org.uk

Sponsor type

Government

Website

http://www.dh.gov.uk/Home/fs/en

Funder(s)

Funder type

Government

Funder Name

Northumbria Healthcare NHS Trust (UK)

Results and Publications

Publication and dissemination planNot provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summaryNot provided at time of registration